X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Following the merger, the two companies will join as one to focus on developing and commercializing MyMD’s novel immunotherapy pipeline assets, including MYMD-1, a novel drug being developed to treat autoimmune and age-related diseases, including extending the human lifespan.
Lead Product(s): Isomyosamine
Therapeutic Area: Immunology Product Name: MYMD-1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: MyMD Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger November 12, 2020
Details:
SARS CoV-2 met both the primary endpoints, safety and immune response. The vaccine candidate was safe even at higher doses and generated a robust immune response against the three SARS-Cov2 antigens.
Lead Product(s): PRAK-03202 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: PRAK-03202
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Premas Biotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
